According to the World Health Organization, 39.9 million people were living with HIV globally in 2023. Out of this, 38.6 million were adults and 53% of the infected people were women and girls. Studies suggest that approximately 5.4 million people aren’t aware that they have HIV. The common treatment for human immunodeficiency virus infection includes antiretroviral therapy (ART). This therapy involves taking a combination of HIV medicines every day. Several clinical trials are ongoing to develop innovative human immunodeficiency virus (HIV 1) infection therapeutics to improve and manage the condition including islatravir, and fostemsavir among others.
The Human Immunodeficiency Virus (HIV 1) Infection Pipeline Report by Expert Market Research gives comprehensive insights into Human Immunodeficiency Virus (HIV 1) Infection drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for human immunodeficiency virus (HIV 1) infection. The human immunodeficiency virus (HIV 1) infection pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from human immunodeficiency virus (HIV 1) infection.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing human immunodeficiency virus (HIV 1) infection development activities is covered in the report.
HIV stands for human immunodeficiency virus, which infects cells of the immune system and makes the body weak to fight against various diseases. When HIV has severely weakened the immune system, it can lead to AIDS (acquired immunodeficiency syndrome). Human immunodeficiency virus infects the white blood cells of the immune system called CD4 cells, destroys them and causes a drop in the white blood cell count. At an initial level, HIV makes the infected person sick with flu-like symptoms and hides in the body for a long without any noticeable symptoms. The virus slowly destroys the T-cells at this phase. When numbers of T-cells get very low, it indicates that HIV has progressed to AIDS.
Currently, there is no cure for HIV. However, there are several human immunodeficiency virus (HIV 1) infection therapeutic drugs available to slow down the progression of HIV. The infection is treated with a combination of medicines, administered orally every day. Taking a combination of medicines is the most effective way to keep HIV from multiplying and destroying the cells. There are several types of ART including nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, pharmacokinetic enhancers, integrase strand transfer inhibitors, and non-nucleoside reverse transcriptase inhibitors among others. As HIV infection is a major health issue, the development of new human immunodeficiency virus (HIV 1) infection drug candidates is crucial for the management of the disease. The focus areas of clinical trials include antiretroviral therapies and vaccines among others. For instance, Vir Biotechnology, Inc. is evaluating the safety of prototype human CMV-based vaccine to manage human immunodeficiency virus infection. These dynamics are impacting the clinical trial landscape significantly.
This section of the report covers the analysis of human immunodeficiency virus (HIV 1) infection emerging drugs based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s human immunodeficiency virus (HIV 1) infection therapeutic assessment covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s human immunodeficiency virus (HIV 1) infection clinical assessment report covers 50+ drug analyses based on the route of administration.
The human immunodeficiency virus (HIV 1) infection report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total clinical trials for human immunodeficiency virus.
The drug molecules categories covered under human immunodeficiency virus (HIV 1) infection pipeline analysis include monoclonal antibodies, peptides, and small molecules. International AIDS Vaccine Initiative is currently evaluating the safety of PGT121 monoclonal antibody for HIV prevention and therapy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for human immunodeficiency virus (HIV 1) infection.
The EMR human immunodeficiency virus (HIV 1) infection report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in human immunodeficiency virus (HIV 1) infection clinical trials:
Tibotec Pharmaceuticals
Vir Biotechnology, Inc.
Janssen Research & Development, LLC
ViiV Healthcare
Janssen-Cilag S.p.A.
Seagen Inc.
Merck Sharp & Dohme LLC
Johnson & Johnson Pte Ltd
Sangamo Therapeutics
TaiMed Biologics Inc.
AbbVie
Gilead Sciences
Alexion Pharmaceuticals, Inc.
Abbott
Others
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and human immunodeficiency virus (HIV 1) infection therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming human immunodeficiency virus (HIV 1) infection drug candidates.
The trial is designed to test the safety of pharmacokinetics and pharmacodynamics of ABBV-181, a drug designed for human immunodeficiency virus-1 infected participants who are taking antiretroviral therapy. The trial is sponsored by AbbVie and is currently under phase I.
The objective of the study is to compare the antiretroviral activity of three drugs, namely, oravirine, tenofovir, and lamivudine in participants infected with the human immunodeficiency virus. The trial is sponsored by Merck Sharp & Dohme LLC and is currently under phase III.
ViiV Healthcare is developing this human immunodeficiency virus (HIV 1) infection drug candidate and is currently under phase III. The study is being conducted to evaluate the safety of the drug in patients receiving CAB and RPV LA injections.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Human Immunodeficiency Virus (HIV 1) Infection Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for human immunodeficiency virus (HIV 1) infection. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into human immunodeficiency virus (HIV 1) infection funding, market trends, regulatory environments, and potential growth opportunities within the human immunodeficiency virus (HIV 1) infection pipeline insights.
Human Immunodeficiency Virus (HIV1) Infection Market
Global Human Immunodeficiency Virus (HIV) Rapid Test Kits Market
Global Zika Virus Therapeutics Market
North America Herpes Simplex Virus Treatment Market
Global Adeno-Associated Virus Vector-Based Gene Therapy Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share